Resistance to chemotherapeutic antimetabolites: A function of salvage pathway involvement and cellular response to DNA damage

British Journal of Cancer

Volumn 75, Issue 7, 1997, Pages 935-945

  Kinsella, A R ^a   Smith, D ^b   Pickard, M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

5 fluorouracil; Methotrexate; N phosphonacetyl L aspartate; p53; Salvage pathways

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CHLORMETHINE; CISPLATIN; CYTARABINE; CYTOTOXIC AGENT; FLUOROURACIL; HYDROXYUREA; MERCAPTOPURINE; METHOTREXATE; NITROSOUREA; SPARFOSIC ACID;

BREAST CANCER; CANCER CHEMOTHERAPY; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA SYNTHESIS; DRUG MECHANISM; DRUG RESISTANCE; DRUG TRANSPORT; GENE AMPLIFICATION; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; TUMOR CELL;

EID: 0030902661     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.164     Document Type: Review

References (129)

1. Advanced Colorectal Cancer Meta-analysis Project (1992) Modulation of fluorouracil by leukovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Onol 10: 896-903
2. Allegra CJ (1990) Antifolates. In Cancer Chemotherapy Principal and Practice Chamber CA and Collins JA (eds), pp. 110-153 Lippincott: Philadelphia
3. Allegra CJ, Fine RL, Drake JC and Chabner BA (1986) The effect of methotrexate on intracellular folate pools in human MCF-7 breast cancer cells evidence for direct inhibition of purine synthesis. J Biol Chem 261: 6478-6485
4. Allegra CJ, Hoang K, Yoh GC, Drake JC and Baram J (1987) Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by mothotrexate. J Biol Chem 262: 13520-13526
5. Almasan A, Linke SP, Paulson TG, Huang LC and Wahl GM (1995) Genetic instability as a consequence of inappropriate entry into and progression through S-phase. Cancer Metastasis Rev 14: 59-73
6. Barhour KN, Berger SH and Berger FG (1990) Single amino acid substitution defines a naturally occurring genetic variant of human thymidylate synthase. Mol Pharmacol 37: 515-518
7. Berger SH, Jenh CH and Johnston LF (1985) Thymidylate synthase overproduction and gene amplification in fluorodeoxuridine resistant human cells. Mol Pharmacol 28: 461-167
8. Blake MC and Azizkhan JC (1989) Transcription factor E2F is required for efficient expression of hamster dihydrofolate reductase gene in vitro and in vivo. Mol Cell Biol 9: 4994-5002
9. Bojan F, Kinsella AR and Fox M (1983) Effect of tumour promoter 12-O-tetradecanoylphorbol-13-acetate on the recovery of methotrexate-. N-phosphonacetyl-L- aspartate-and cadmium-resistant colony-forming mouse and hamster cells. Cancer Res 43: 5217-5221
10. Borchers AH, Kennedy DA and Straw JA (1990) Inhibition of DNA excision repair by methotrexate in Chinese ovary cells following exposure to ultraviolet irradiation or ethylmethane sulfonate. Cancer Res 50: 1786-1789
11. Boyle JM, Hey Y and Fox M (1989) N'ucleotide ectoenzyme activities of human and Chinese hamster fibroblasts in tissue culture. Biochem Genet 27: 655-659
12. Brennan J, O'Connor T, Makuch RW, Simmons AM, Russell E, Linnoila RI, Phelps RM, Gazdar AF, Inde DC and Johnson BE (1991) Myc family DNA amplification in 107 tumours and tumour cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res 51: 1708-1712
13. Brett MC, Pickard M, Green B, Howel-Evans A, Smith D, Kinsella A and Poston G (1996) p53 protein over expression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Surg Oncol 22: 182-185
14. Brown PC, Tlsty TD and Schimke RT (1983) Enhancement of methotrexate resistance and dihydrofolate reductase gene amplification by treatment of mouse 3T6 cells with hydroxyurea. Mol Cell Biol 3: 1097-1107
15. Cabral S, Leis S, Bover L, Nembrot M and Mordoh J (1984) Dipyridamole inhibits reversion by thymidine of metholrexate effect and increases drug uptake in Sarcoma 180 cells. Proc-Natl Acad Sci USA 81: 3200-3303
16. Cadman F and Benz C (1980) Uridine and cytidine metabolism following inhibition of de novo pyrimidine synthesis by pyrazofurin. Biochimica et Biophysica Act 609: 372-382
17. Camici M, Tozzi MG, Allegrini S, Delcorso A, Sanfilippo O, Daidone MG, Demarco C and Ipata PL (1990) Purine salvage enzyme activities in normal and neoplastic human tissues. Cancer Biochem Biophys 11: 201-209
18. Chabner BA and Collins JA (1990) Cancer Chemotherapy. Principles and Practice. Lippincott: Philadelphia
19. Chan TCK and Howell SB (1985) Mechanism of synergy between N-Phosphonacetyl-L- aspatate and dipyridamole in a human ovarian carcinoma cell line. Cancer Res 45: 3598-3604
20. Cheng YC and Nakayama K (1983) Effects of 5-fluoro-2-deoxyuridine on DNA metabolism in Hela cells. Molec Pharmacol 23: 171-174
21. Chu E, Drake JC and Koeller DM (1991) Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 39: 136-143
22. Cillo C, Ling C and Hill RP (1989) Drug resistance in KHT fibrosarcoma cell lines with different metastatic ability. Int J Cancer 43: 107-111
23. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852
24. Collins KD and Stark GR (1971) Aspartate transcarbamylase interaction with the transition state analogue N-(phosphonacetyl)-L-aspartate. J Biol Chem 246: 6599-6605
25. Chresta CM and Hickman JA (1996) Oddball p53 in testicular tumours. Nature Med 2: 745-746
26. Chresta CM, Masters JRW and Hickman JA (1996) Hypersensitivity of human testicular tumours to etoposide-induced apoptosis associated with functional p53 and a high Bax. Bc12 ratio. Cancer Res 56: 1834-1841
27. Di Leonardo A. Linke SP, Clarkin K and Wahl GM (1994) DNA damage triggers a prolonged p53-dependent G7-arrest and long-term induction of CiPI in normal human fibroblasts. Genes Devel 8: 2540-2551
28. Dive C and Hickman JA (1991) Drug target interactions: only the first step in the commitment to a programmed cell death. Br J Cancer 64: 192-196
29. Dowell SP and Hall PA (1994) The clinical relevance of the p53 tumour suppresser gene. Cytopathology 5: 133-145
30. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ and Reed SI (1994) p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023
31. Erilichman C (1992) Pharmacology of anticancer drugs. In The Basic Science of Oncology Tannock IF and Hill RP. (eds) McGraw Hill
32. Evans RM, Laskin JD and Hakala MT (1980) Assessment of growth limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res 40: 4113-4122
33. Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW and O'Connor PM (1994) p53 mutations are associated with decreased sensitivity of human lymphanic cells to DNA-damaging agents. Cancer Res 54: 5824-5830
34. Flintoff WE, Davidson SV and Siminovitch L (1976) Isolation and partial characterisation of three methotrexate-resistant phenotypes from Chinese hamster ovary cells. Somat Cell Gen 2: 245-261
35. Fox M, Boyle JM and Kinsella AR (1991) Nucleoside salvage and resistance to antimetabolite anticancer agents. Br J Cancer 64 428-436
36. Fritsche M, Haessler C and Brandner G (1993) Induction of nuclear accumulation of the tumour suppressor protein p53 by DNA damaging agents. Oncogene 8: 307-318
37. Giulotto E, Knights C and Stark GR (1987) Hamster cells with increased rates of DNA amplification, a new phenotype. Cell 48: 837-845
38. Gordon JL (1985) Extracellular ATP, effect, sources and fate. Biochern J 233: 309
39. Goz B and Jeffs L (1994) The enhancement of the frequency of resistance to N-Phosphonacetyl-L-aspartate and methotrexate by 1-B-D-arabinofuranosylcytosine. The effect of dipyridamole. J Pharmacol Exp Ther 270: 480-484
40. Goz B, Carl PL and Tlsty TD (1989) 1-B-D Arabino-furanosylcytosine enhancement of resistance to several antineoplastic drugs in mammalian tissue culture cells. Mol Pharmacol 36: 360-365
41. Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
42. Grem JL (1992) Biochemical modulation of fluorouracil by dipyridamole: preclinical and clinical experience. Semin Oncol 19: 56-65
43. Grem JL and Fischer PH (1985) Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res 45: 2967-2972
44. Grem JL and Fischer PH (1986) Alteration of flurouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels. Cancer Res 46: 6191-6199
45. Grem JL and Fischer PH (1989) Enhancement of 5-fluorouracil's anticancer activity by dipyridamole. Pharmac Ther 40: 349-371
46. Hall PA and Lane DP (1994) p53 in tumour pathology: can we trust immunohistochemistry? -revisited. J Pathol 172: 1-4
47. Harper JW, Adami GR, Wei N, Kegomarsi K and Elledge SJ (1993) The p21 Cdk-interacting protein Cipl is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816
48. Harris CC and Hollstein M (1993) Clinical implications of the p53 tumour suppressor gene. New Eng J Med 329: 1318-1327
49. Hartwell LH and Kastan MB (1994) Cell cycle control and cancer. Science 266: 1821-1828
50. Hecker S, Sauerbrey A and Volm M (1994) p53 expression and poor prognosis in childhood acute lymphoblastic leukaemia. Anticancer Res 14: 2759-2761
51. Heidelberger C, Chauduri NK, Danenberg P et al (1957) Fluorinated pyrimidines a new class of tumour inhibitory compound. Nature 179: 663-666
52. Heidelberger C. Danenberg PV and Moran RG (1983) Fluorinated pyrimidines and their nucleosides. Adv Enzymol 54: 57-119
53. Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991) p53 mutations in human cancers. Science 253: 49-53
54. Houghton JA, Maroda SJ Jnr, Philips JO and Houghton PJ (1981) Biochemical determinants of responsiveness to 5-fluorouracil and its deviates in xenografts of human colorectal adenocarcinomas in mice. Cancer Res 41: 144-149
55. Huang L-C, Clarkin KC and Wahl GM (1996) Sensitivity and selectivity of DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci USA 93: 4827-4832
56. Ishizaka Y, Chernov MV, Burns CM and Stark GR (1995) p53-dependent growth arrest of REF 52 cells containing newly amplified DNA. Proc Nutl Acad Sci USA 92: 3224-3228
57. Jastreboff MM, Kedzherska B and Rode W (1983) Altered thymidylate synthase in fluoro-deoxyuridine-resistant cultured hepatoma cells. Biochem Pharmacol 32: 2259-2267
58. Johnson LF (1994) Postranscriptional regulation of thymidylate synthase gene expression. J Cell Biochem 54: 387-392
59. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
60. Kennedy DG, Van Den Berg HW, Clarke R and Murphy RF (1986) Enhancement of methotrexate cytotoxicity towards the MDA, MB. 436 human breast cancer cell line by dipyridamole. Biochem Pharmacol 35: 3053-3056
61. Kuerbitz SJ, Plunkett BS, Walsh WV and Kastan MB (1992) Wild-type p53 in a cell cycle checkpoint determinant following invadiation. Proc Natl Acad Sci USA 89: 7491-7495
62. Kinsella AR and Haran MS (1991) Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts. Cancer Res 51: 1855-1859
63. Lane DP (1992) p53 guardian of the genome. Nature 358: 15-16
64. Levine AJ, Momand J and Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453-456
65. Levine AJ, Perry A, Chang A, Silver A, Dittmer D, Wu M and Welsh D (1994) The 1993 Walter Hubert Lecture: The role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 69: 409-416
66. Li WW, Fan J, Hochhauser D, Banerjee D, Zielinski Z, Almasan A, Yin YX. Kelly R. Wahl GM and Bertino JR (1995) Lack of a functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cells. Proc Natl Acad Sci USA 92: 10436-10440
67. Linke SP, Clarkin KC, Di Leonardo A, Tsou A and Wahl GM (1996) A reversible. p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Devel 10: 934-947
68. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type P53. Cell 70: 923-935
69. Lorico A, Toffoli G, Boiocchi M, Erba E, Broggini M, Rappa G and Dincalci M (1988) Accumulation of DNA strand breaks in cells exposed to Methotrexate or N 10-propargyl-5, 8-dideazafolic acid. Cancer Res 48 2036-2041
70. Lowe S, Schmitt EM, Smith SW, Osborne BA and Jacks T (1993a) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849
71. Lowe SW, Ruley EH, Jacks T and Housman DE (1993b) p53-dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell 74: 957-967
72. Lucke-Huhle C (1989) Review: Gene amplification - a cellular response to genotoxic stress. Mol Taxicol 2: 237-253
73. Lucke-Huhle C (1994) Permissivity for methotrexate-induced DHFR gene amplification correlates with the metastatic potential of rat adenocarcinoma cells. Carcinogenesis 15: 695-700
74. Lutzker SG and Levine AJ (1996) A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation. Nature Med 2: 804-809
75. Machover D, Schwarzenberg L, Guldschmidt E et al (1982) Treatment of advanced colorectal and gastric adenocarcinoma with 5-FU combined with high-dose folinic acid: a pilot study, Cancer Treat Rep 66: 1803-1807
76. Madoc-Jones H and Bruce WR (1968) On the mechanism of the lethal action of 5-fluorouracil on mouse L cells. Cancer Res 28: 1976-1981
77. Mandel G (1969) The incorporation of 5-fluorouracil into RNA and its molecular consequences. In Progress in Molecular and Subcellular Biology. Hahn FE (ed.). pp. 82-135. Springer: New York
78. Martin DS, Stozfi RL, Sawyer RC, Spiegelman S, Casper ES and Young CW (1983) Therapeutic utility of utilising low doses of N-(phosphonacetyl)-L- aspartate in combination with 5-fluorouracil. A murine study with clinical relevance. Cancer Res 43: 2317-2321
79. Marz R. Wohlhueter RM and Plagemann PGW (1977) Growth rate of cultured Novikoff rat hepatoma cella as a function of the rate of thymidine and hypoxanthine transport. J Membr Biol 34: 277-288
80. Mcllwrath AJ, Vasey PA, Ross GM and Brown R (1994) Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on WT p53 for radiosensitivity. Cancer Res 54: 3718-3722
81. Miller EM, Willson JF and Fischer PH (1987) Folinic acid alters the mechanism by which dipyridamole increases the toxicity of fluorouracil in human colon cancer cells. Proc Am Assoc Cancer Res 28: 326
82. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hofmann B and Reed JC (1994) Tumour suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805
83. Moyer JD, Smith PA, Levy EJ and Handschumacher RE (1982) Kinetics of N-(phosphonacetyl)-L-aspartate and pyrozafurin depletion of pyrimidine ribonucleotide and deoxynucleotide pools and their nucleic acid synthesis in intact and permebilised cells. Cancer Res 42: 4525-4531
84. Natsumeda Y, Ikegami T, Olah E and Weber G (1989) Significance of purine salvage in circumventing the action of antimetabolites in rat hepatoma cells. Cancer Res 49: 88-92
85. Nelson JA and Drake S (1984) Potentiation of methotrexate toxicity by dipyridamole. Cancer Res 44: 2493-2496
86. Nelson WG and Kastan MB (1994) DNA strand breaks: the DNA template alterations that trigger P53-dependent DNA damage response pathways. Mol Cell Biol 14: 1815-1823
87. Noda A, Ning Y, Venable SF, Pereira-Smith OM and Smith JR (1994) Cloning of senescent cell-derived inhibitors of DNA synthesis using and expression screen. Exp Cell Res 211: 90-98
88. Otto E, Mccord S and Tlsty TD (1989) Increased incidence of CAD gene amplification in tumorigenic rat lines as an indicator of genomic instability. J Biol Chem 264: 3390-3396
89. Parker WD and Cheng YC (1990) Metabolism and mechanism of 5-fluorouracil. Pharmac Ther 4: 381-395
90. Perry ME, Commane M and Stark GR (1992) Simian virus 40 large tumour antigen alone or two co-operating oncogenes convert REF 52 cells to a state permissive for gene amplification. Proc Natl Acad Sci USA 89: 8112-8116
91. Plagemann PGW, Marz R and Wohlhueter RM (1978) Transport and metabolism of deoxycytidine and I-B-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation and regulation of triphosphate synthesis. Cancer Res 38: 978-989
92. Pickard M and Kinsella AR (1996) Influence of both salvage and DNA damage response pathways with resistance to chemotherapeutic antimetabolites. Biochem Pharmacol 52: 425-431
93. Pickard M, Dive C and Kinsella AR (1996) Differences in resistance to 5-FU as a function of cell cycle delay and not apoptosis. Br J Cancer 72: 1389-1396
94. Reed JC (1994) Bcl-2 and the regulation of programmed cell death. Cell Biol 124: 1-6
95. Rice GC. Hoy C and Schimke RT (1986) Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci USA 83: 5978-5982
96. Schimke RT (1984a) Gene amplification, drug resistance and cancer. Cancer Res 44: 1735-1741
97. Schimke RT (1984b) Gene amplification in cultured animal cells. Cell 37: 705-713
98. Schimke RT, Sherwood SW, Hill AB and Johnston RN (1986) Over replication and recombination in higher eukaryotes potential consequences and biological implications. Proc Natl Acad Sci USA 83: 2157-2161
99. Schwab M and Amler LC (1990) Amplification of cellular oncogenes. A predictor of clinical outcome in human cancer. Genes Chromosomes Cancer 1: 181-193
100. Schwartz J, Alberts D, Einspahr J, Peng YM and Spears P (1987) Dipyridamole potentiation of FUDR activity against human colon cancer in vitro and in patients. Proc Am Soc Chem Oncol 6: 83
101. Sinkeler S, Joesten E, Weaver R, Binkhorst R and Oel L (1986) Skeletal muscle adenosine, inosine and hypoxanthine release following ischaemic forearm exercise in myoadenylate deaminase deficiency and McArdle's disease. Adv Exp Med Biol 195B: 517
102. Slansky JE, Kaelin WG and Farnham PJ (1993) A protein synthesis-dependent increase in E2F1mRNA correlates with growth regulation of the dihydrofolate reductase promoter. Mol Cell Biol 13: 1610-1618
103. Sommer A and Santi DV (1974) Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalenty hound 5′-fluoro-2′-deoxyuridylate and methylene tetrachloride. Biochem Biophys Res Commun 57: 689-696
104. Sotos GA, Grogan L and Allegra CJ (1994) Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treatment Rev 20: 11-49
105. Stark GR (1986) DNA - amplification in drug resistant cells and in tumours. Cancer Surv 5: 1-23
106. Stark GR (1993) Regulation and mechanisms of gene amplification. Adv Cancer Res 61: 87-114
107. Stark GR and Wahl GM (1984) Gene amplification. Ann Rev Biochem 53: 447-491
108. Stark GR, Debatisse M, Giulotto E and Wahl GM (1989) Recent progress in understanding mechanisms of mammalian gene amplification. Cell 57: 901-908
109. Swyryd EA, Seaver SS and Stark GR (1974) N-(Phosphonacetyl)-L-aspartate transcarbmylase blocks proliferation of mammalian cells in culture. J Biol Chem 249: 6945-6950
110. Szallasi A, Fox M and Kinsella AR (1988) TPA-enhancement of the recovery of methotrexate and N-(phosphonacetyl)-L-aspartate-resistant mouse 3T6 cell clones is associated with transient alteration of cell cycle progression. Int J Cancer 42: 84-86
111. Tlsty TD (1990) Normal diploid human and rodent cells lack a detectable frequency of gene amplification. Proc Natl Acad Sci 87: 3132-3136
112. Tlsty TD, Brown PC, Johnston R and Schimke RT (1982) Enhanced frequency of generation of methotrexate resistance and dihydrofolate gene amplification in cultured mouse and hamster lines. In Gene Amplification, Schimke RT (ed.), pp. 231-238 , Cold Spring Harbor Laboratory: Cold Spring Harbor, New York
113. Tlsty TD, Brown PC and Schimke RT (1984) UV radiation facilitates methotrexate resistance and dihydrofolate reductase gene amplification in cultured murine cells. Mol Cell Biol 4: 1050-1056
114. Tlsty TD, Margolin BH and Lum K (1989)Differences in the rates of gene amplification in non-tumorigenic and imnorigenic cell lines as measured by Luria-Deltrück fluctuationanalysis. Proc Natl Acad Sci 86: 9441-9445
115. Tsvaris N, Zinelis A, Karvounis N, Beldecos D, Mylonacis N, Zamunis N, Bacoyannis C, Valilis P, Antonopoulos A and Kosmidis P (1990) Multimodal biochemical modulation of 5-fluorouracil activity in advanced colorectal cancer with allopurinol, folinic acid and dipyridamol. J Chemother 2: 123-126
116. Ullman B, Lee M, Martin DW and Santi DV (1978) Cytotoxicity of 5-fluoro-2-deoxyuridine: requirement for reduced folate cofactors and antagonism of methotrexate. Proc Natl Acad Sci USA 75: 980-983
117. Vogel SJ, Presant CA and Ratkin GA (1979) Phase 1 study of thymidine plus 5-fluorouracil infusions in advanced colorectal carcinoma. Cancer Treat Rep 63: 1-5
118. Van Mouwerik TJ, Pangallo CA, Willson JKV and Fischer PH (1987) Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole. Biochem Pharmacol 36: 809-814
119. Wahl GM, Padgett RA and Stark GR (1979) Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(Phosphonacetyl)-L-aspartate-resistant hamster cells. J Biol Chem 254: 8679-8689
120. Wattell E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I. Morel P and Fanaux (1994) P53 mutations are associated with resistance to chemotherapy and short survival in haematologic malignancies. Blood 84: 3148-3157
121. Waxman S, Bruckner H. Wagle A and Schreiber C (1978) Potentiation of 5-fluorouracil (5FU). Antimetabolic effect by leukovorin (LV). Proc Am Assoc Cancer Res 19: 149
122. Weber G (1993) Biochemical strategy of cancer cells and the design of chemotherapy: GHA Clowes Memorial Lecture. Cancer Res 43: 3466-3492
123. Weber G and Prajda N (1994) Targeted and non-targeted actions of anti-cancer drugs. Adv Enzyme Regul 34: 71-89
124. Windle BE and Wahl GM (1992) Molecular dissection of mammalian gene amplification: new mechanistic insights revealed by analyses of very early events. Mutat Res 276:199-224
125. Wright JA, Smith HS, Watt FM, Hancock MC, Hudson DL and Stark GR (1990) DNA amplification is rare in normal human cells. Proc Natl Acad Sci USA 87: 1791-1795
126. Xiong Y, Hannon H, Zhang H, Casso D, Kobayashi R and Beach D (1993) p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704
127. Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM (1992) Wild type P53 restores cell cycle control and inhibits gene amplification in cells with mutant P53 alleles. Cell 70: 937-948
128. Yoshia T. Stark GR and Hoogenraad NJ (1974) Inhibition by N-(phosphonacetyl)-L-asparate of aspartate transcarbamylase activity and drug-induced cell proliferation in mice. J Biol Chem 249: 6951-6955
129. Yoshioka A, Tanaka S, Hiraoka O, Koyama Y, Hirota Y, Ayusawa D, Seno T. Garrett C and Wataya Y (1987) Deoxynbonucleoside triphosphate imbalance. 5-fluorodeoxyuridine-induced DNA double strand breaks in mouse. FM3A cells and the mechanism of cell death. J Biol Chem 262: 8235-8241